Nov 29 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP ENTERS INTO SECOND CLINICAL TRIAL COLLABORATION AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER FOR NEW COMBINATION STUDY OF ITS FIRST-IN-CLASS LAG-3 CANDIDATE, EFTILAGIMOD ALPHA, AND AVELUMAB TO TREAT UROTHELIAL CANCER
- IMMUTEP ENTERS INTO SECOND CLINICAL TRIAL COLLABORATION AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER FOR NEW COMBINATION STUDY OF ITS FIRST-IN-CLASS LAG-3 CANDIDATE, EFTILAGIMOD ALPHA, AND AVELUMAB TO TREAT UROTHELIAL CANCER
- IMMUTEP LTD - FIRST PATIENT IS EXPECTED TO BE ENROLLED AND DOSED IN H1 OF CALENDAR YEAR 2023
- IMMUTEP LTD - UNDER AGREEMENT, IMMUTEP AND MERCK KGAA, DARMSTADT, GERMANY WILL JOINTLY FUND INSIGHT-005 STUDY
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.030(13.0%) |
Mkt cap ! $381.6M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 26.3¢ | 23.3¢ | $1.116M | 4.407M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25156 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.5¢ | 809798 | 9 |
View Market Depth
| Last trade - 16.10pm 15/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |